Skip to main content
SpringerLink
Log in

Treatment optimization for recurrent hepatoblastoma: retrospective study from a hepatoblastoma cohort in Southern China

  • Original Article
  • Published:
Pediatric Surgery International Aims and scope Submit manuscript

Abstract

Purpose

The present study aimed to explore the clinical characteristics and optimal treatments of RHB patients.

Methods

We retrospectively collected 42 RHB cases and 161 primary HB (PHB) cases. Clinical characteristics were compared between RHB and PHB patients. The risk factors related to overall survival (OS) and progression-free survival (PFS) in RHB patients were explored by COX regression analysis. Patients were further divided into curable and refractory subgroup by treatments. Propensity score match (PSM) analysis was performed to match recurrent curable patients from 145 curable PHB patients from the same cohort. PFS was further compared between 34 pairs of primary and recurrent curative HB patients.

Results

Recurrence treatment and number of relapsed tumors were significantly related with both OS and PFS of RHB patients (p < 0.05). Chemotherapy regimen alteration was also risk factor of PFS for RHB (HR = 4.26; 95% CI = 1.54–11.78; p = 0.005). RHB patients underwent curable treatment had better prognosis, compared with recurrent refractory subgroup (p < 0.001). Matched curable PHB patients demonstrated no significant difference of 3-year PFS with curable RHB patients (p = 0.540).

Conclusion

Curable RHB patients might get benefit from surgery or ablation with similar prognosis with primary curable HB patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hooks A, Fazli L, Ernault D-S et al (2018) New insights into diagnosis and therapeutic options for proliferative hepatoblastoma. Hepatology 68:89–102. https://doi.org/10.1002/hep.29672

    Article  CAS  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551

    Article  PubMed  Google Scholar 

  3. Shi C, Masand H, Goss V (2017) Vascular invasion is a prognostic indicator in hepatoblastoma. J Pediatr Surg 52:956–961. https://doi.org/10.1016/j.jpedsurg.2017.03.017

    Article  PubMed  Google Scholar 

  4. Trobaugh-Lotrario AD, Meyers RL, Feusner JH (2016) Outcomes of patients with relapsed hepatoblastoma enrolled on Children’s Oncology Group (COG) phase i and ii studies. J Pediatr Hematol Oncol 38:187–190. https://doi.org/10.1097/mph.0000000000000474

    Article  PubMed  Google Scholar 

  5. Zhang C, Yao Li, Zhong L (2020) Novel treatment of refractory/recurrent pulmonary hepatoblastoma. Pediatr Int 62:324–329. https://doi.org/10.1111/ped.14134

    Article  CAS  PubMed  Google Scholar 

  6. Venkatramani R, Furman WL, Fuchs J, Warmann SW, Malogolowkin MH (2012) Current and future management strategies for relapsed or progressive hepatoblastoma. Paediatr Drugs 14:221–232. https://doi.org/10.2165/11597740-000000000-00000

    Article  PubMed  Google Scholar 

  7. Hou JY, Yeh TC, Huang TH, Sheu JC, Liu HC (2021) A retrospective study of clinical features and outcome in patients with refractory or recurrent hepatoblastoma: a single institution experience. Pediatr Neonatol 62:400–405. https://doi.org/10.1016/j.pedneo.2021.03.018

    Article  PubMed  Google Scholar 

  8. Agarwala G, Bansal V, Prasad A et al (2017) Management of hepatoblastoma: ICMR consensus document. Indian J Pediatr 84:456–464. https://doi.org/10.1007/s12098-017-2301-9

    Article  PubMed  Google Scholar 

  9. Semeraro B, Maibach Z, Casanova B et al (2013) Relapses in hepatoblastoma patients: clinical characteristics and outcome–experience of the International Childhood Liver Tumour Strategy Group (SIOPEL). Eur J Cancer 49:915–922. https://doi.org/10.1016/j.ejca.2012.10.003

    Article  CAS  PubMed  Google Scholar 

  10. Hetzer V, Entenmann H, Schullian P et al (2020) Stereotactic radiofrequency ablation of a variety of liver masses in children. Int J Hyperth 37:1074–1081. https://doi.org/10.1080/02656736.2020.1822549

    Article  Google Scholar 

  11. Yevich C, Gravel F, Brugières V-C et al (2019) Reiterative radiofrequency ablation in the management of pediatric patients with hepatoblastoma metastases to the lung, liver, or bone. Cardiovasc Intervent Radiol 42:41–47. https://doi.org/10.1007/s00270-018-2097-7

    Article  PubMed  Google Scholar 

  12. Cui Yu, Gu C, Liu D et al (2019) Microwave ablation assisted by three-dimensional visualization system as local therapy for relapsed hepatoblastoma: a small pilot study. Abdominal Radiol 44:2909–2915. https://doi.org/10.1007/s00261-019-02011-5

    Article  Google Scholar 

  13. Chinese Anti-Cancer Association Pediatric Committee, China Medical Association Pediatric Onco-surgery Group (2017) Expert consensus for multidisciplinary management of hepatoblastoma (CCCG-HB-2016). Chin J Pediatr Surg 38:733–739

    Google Scholar 

  14. Eisenhauer T, Bogaerts S, Sargent F et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

    Article  CAS  PubMed  Google Scholar 

  15. Meyers M, Hiyama H, Krailo R et al (2017) Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s Hepatic tumors International Collaboration. Lancet Oncol 18:122–131. https://doi.org/10.1016/s1470-2045(16)30598-8

    Article  PubMed  Google Scholar 

  16. Chen H, Ling Yu, Cheng L et al (2021) Percutaneous thermal ablation versus open liver resection for recurrent hepatoblastoma: a retrospective study. Int J Hyperth 38:1086–1091. https://doi.org/10.1080/02656736.2021.1941310

    Article  CAS  Google Scholar 

  17. Liu Z, Huang Z, Jiang S et al (2015) First experience of ultrasound-guided percutaneous ablation for recurrent hepatoblastoma after liver resection in children. Sci Rep 5:16805. https://doi.org/10.1038/srep16805

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hirsch P, Morcrette R, Monteiro M et al (2021) Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer. Cancer Discov 11:2524–2543. https://doi.org/10.1158/2159-8290.CD-20-1809

    Article  CAS  PubMed  Google Scholar 

  19. Sumazin C, Treviño S, Hampton P et al (2017) Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology 65:104–121. https://doi.org/10.1002/hep.28888

    Article  CAS  PubMed  Google Scholar 

  20. Gay S, Park D, Groves H et al (2021) Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(346–360):e347. https://doi.org/10.1016/j.ccell.2020.12.014

    Article  CAS  Google Scholar 

  21. Czauderna H, Hiyama R, Krailo M et al (2016) The Children’s Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer 52:92–101. https://doi.org/10.1016/j.ejca.2015.09.023

    Article  PubMed  Google Scholar 

  22. Sato K, Suzushino K, Okada I et al (2021) Predicting post-hepatectomy liver failure using intra-operative measurement of indocyanine green clearance in anatomical hepatectomy. World J Surg 45:3660–3667. https://doi.org/10.1007/s00268-021-06289-9

    Article  PubMed  Google Scholar 

  23. Chen Wu, Cheng W, Rong Wu et al (2021) Phase 2 study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with HCC. Hepatology 74:2595–2604. https://doi.org/10.1002/hep.31993

    Article  PubMed  Google Scholar 

  24. Xia Li, Liu W, Qian Lu et al (2020) Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol 6:255–263. https://doi.org/10.1001/jamaoncol.2019.4477

    Article  PubMed  Google Scholar 

Download references

Funding

This work was supported by China Postdoctoral Science Foundation (2021M693650).

Author information

Author notes

  1. Yuanqi Wang, Huadong Chen and Yixuan Liu are contributed equally.

Authors and Affiliations

  1. Department of Liver Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China

    Yuanqi Wang

  2. Department of Pediatric Surgery, The First Affiliated Hospital of Sun Yat-sen University, No. 58, ZhongShan 2nd Road, Guangzhou, 510080, China

    Huadong Chen, Zhihai Zhong, Pengfei Gao, Zhichong Zhang, Jinbiao She, Juncheng Liu & Hong Jiang

  3. Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China

    Yixuan Liu

  4. Division of Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, Guangdong, China

    Han Xiao

  5. Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, 510260, China

    Xiaoshuai Wang

  6. Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, ZhongShan 2nd Road, Guangzhou, 510080, China

    Leilei Huang

Authors
  1. Yuanqi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huadong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yixuan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Han Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoshuai Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhihai Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pengfei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhichong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jinbiao She
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Juncheng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Leilei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hong Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YW, HJ, LH and HC designed the whole research. YL, LH, ZZ, PG, ZZ, JS and JL collected data. YL, YW and HC performed data interpretation and analysis. YW, HX, XW, HC and YL wrote the main manuscript text. HJ and LH gave critical revision. All authors reviewed the manuscript.

Corresponding authors

Correspondence to Leilei Huang or Hong Jiang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of interest

The authors have no competing interests to declare that are relevant to the content of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Chen, H., Liu, Y. et al. Treatment optimization for recurrent hepatoblastoma: retrospective study from a hepatoblastoma cohort in Southern China. Pediatr Surg Int 38, 1031–1039 (2022). https://doi.org/10.1007/s00383-022-05126-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00383-022-05126-x

Keywords

Search

Navigation